Kornimate/medical-research-clean huggingface dataset:
long-term alterations of host-microbiome interactions and cardiovascular and respiratory diseases progression after pneumonia

Conditions: Hospital Acquired Pneumonia (HAP); Cardiovascular and Respiratory Disease

Summary: the homi-lung - hap study is part of the homi-lung project, funded by the horizon europe program. the "homi-lung" project is an international, interdisciplinary project that aims to better understand the causal links between respiratory tract infections (i.e. pneumonia) and the progression of cardiovascular disease. more specifically, the project aims to quantify the burden of cardiovascular disease after pneumonia and assess patients\&#39; acceptability of long-term health alterations, as well as to define pneumonia endotypes with distinct pathobiological mechanisms associated with exacerbation of cardiovascular disease.


Eligibility criteria:
inclusion criteria: group a (patients with acute cardiac disease) * male or female * age ≥ 40years old * hospitalized for acute coronary syndrome for less than 7 days. * informed consent from the patient * person insured under a health insurance scheme group b (patients with chronic cardiovascular disease) * male or female, * age ≥ 40 years old * undergoing coronary artery by-pass surgery * hospitalized in intensive care unit for \&gt; 12 hours * informed consent from the patient * person insured under a health insurance scheme group c (patients at risk of cvrd without chronic cardiovascular disease) * male or female, * age ≥ 40 years old * familial high levels of cholesterol or triglycerides * with no personal history of cvrd, with a recent negative cardiac exercise test (last test inferior to 12 months) * follow-up for lipid abnormalities at high risk of cvrd events * informed consent from the patient * person insured under a health insurance scheme group d (patients with hap) * male or female * age ≥ 40years old * with one or more risk factors for cvd among: smoking, abnormal lipidic levels, high blood pressure, obesity, diabetes mellitus, chronic kidney disease * cured from mechanically ventilated hap during the current hospitalization * informed consent from the patient or relatives * person insured under a health insurance scheme exclusion criteria: * o groups a, b, c and d * age \&gt;80 years old * immunosuppression pre-existing to the index hospitalisation, defined as lymphopenia \&lt; 500 elements/mm3, haematologic cancer, aplasia, chemotherapy/radiotherapy for cancer within 3 months prior to the inclusion, or anti-graft rejection drug. * pregnant women, breastfeeding women. * adults under guardianship or trusteeship. * low probability of survival at day 28. o groups a, b, c * community-acquired pneumonia or hospital-acquired pneumonia within the last year.

Keywords: hospital-acquired pneumonia cardiovascular and respiratory diseases respiratory microbiome
this study is an open-label trial of pregabalin in patients with fibromyalgia

Conditions: Fibromyalgia

Summary: the main purpose of this protocol is to evaluate the long-term safety of pregabalin in patients who participated in the previous fibromyalgia study a0081100 and who wish to receive open-label pregabalin therapy.


Eligibility criteria:
inclusion criteria: * patients must have met the inclusion criteria for the preceding fibromyalgia protocol a0081100, and must have received pregabalin/placebo under double-blind conditions. exclusion criteria: * patients may not participate in the study if they experienced a serious adverse event during the previous fibromyalgia study a0081100 which was determined to be related to the study medication by the investigator or the sponsor.
identification of non invasive biomarkers of immune endothelial injury and repair associated with cardiac allograft vasculopathy

Conditions: Cardiac Allograft Vasculopathy

Summary: heart transplantation is the best option for patients with end-stage heart failure. cardiac allograft vasculopathy (cav) is the leading cause of death following cardiac transplantation and is not managed by current therapies. its pathogenesis traduces in an accelerated form of coronary artery disease (cad) with similarities to atherosclerosis but also particular features of endothelial dysfunction associated to the alloimmune conflict and humoral responses toward the graft. intravascular ultrasound (ivus) is the validated invasive method for late cav diagnosis, but occurs lesions are established. identification of reliable non-invasive early endothelial injury biomarkers that reflect mechanisms of cardiac damage thus remain a major challenge to optimize therapeutic management of post transplant morbidity. endothelial dysfunction is a central feature of both cav and cad and results from a desquilibrium in the balance of endothelial lesion and repair that is partly controlled by recipient immune system. through their expression of receptors sensing antibodies (fcr cd16) and endothelial stress-induced signals (cx3cr1 fractalkine receptor and nkg2d mica receptors), natural killer (nk) cells represent effector cells with unique potential to generate both humoral and innate immune injury of graft endothelium.


Eligibility criteria:
inclusion criteria: * subject \> 18 years at the time of the inclusion, * subject having benefited from a heart transplant more than 11 months ago in the service of cardiac surgery concerned whatever is the treatment to immunosuppresseur current * subject benefiting from a coronarography within the framework of their surveillance comment-clerk's office beyond 12 months * subject having given their consent * affiliated to the social security \* htc with cardiac allograft vasculopathy: * subject with coronaropathies diagnosed by the coronarography \* tc without cardiac allograft vasculopathy: * subject without coronaropathies diagnosed by the coronarography \* untransplanted * untreated subject by immunosuppresseurs * subject without antécédaent of transfusion * subject without history of transplantations * subject with coronaropathies diagnosed by a coronarography exclusion criteria: * presenting a contraindication to the coronarography * subject refusing to practise the examination of coronarography * subject reaches(affects) of a cancer other one than cutaneous * subject achieves of hepatic incapacity (alat and\\or asat \> 3n)

Keywords: identify early non invasive markers that index the endothelial lesion/ regeneration potential in association with cav in heart transplanted recipients (htr)
thalamic deep brain stimulation for spasmodic dysphonia- debussy trial

Conditions: Spasmodic Dysphonia; Laryngeal Dystonia; Deep Brain Stimulation

Summary: laryngeal dystonia (ld), also commonly referred to as spasmodic dysphonia, is a neurological voice disorder characterized by involuntary dystonic contractions of the laryngeal muscles. current treatments such as botox and voice therapy only provide temporary relief and thus, the investigators are exploring new strategies to provide long-term, sustained improvement. deep brain stimulation (dbs) is a neurosurgical procedure that involves the implantation of electrodes to deliver electrical stimuli to specific brain regions. it is the standard surgical treatment for many other movement disorders such as parkinson's disease, essential tremor, and primary dystonia. this trial has been designed to test the hypothesis that dbs can improve the vocal dysfunction of ld.


Eligibility criteria:
inclusion criteria: * clinically diagnosed isolated laryngeal dystonia (adductor spasmodic dysphonia) * able to give informed consent * patients who fall into the age range of 18-75 years old * patients with inadequate medical and btx management of spasmodic dysphonia exclusion criteria: * dystonia present in other body parts (i.e- eyes, neck, limbs) in addition to larynx * history of laryngeal denervation surgery for spasmodic dysphonia * history of intracranial pathology (such as multiple sclerosis, tumors, or aneurysms) that may account for dystonia or essential tremor. * history or evidence of ongoing psychiatric or neurodegenerative disorders (such as parkinson's disease, alzheimer's disease). * incompetent adults or those unable to communicate.
robot assisted total hip arthroplasties

Conditions: Hip Arthropathy

Summary: this is a randomized controlled, multicenter study. according to the inclusion criteria, volunteers were recruited from patients undergoing total hip arthroplasty. after signing the informed consent, the subjects were assigned to the experimental group and the control group through the central randomization system. the researchers will complete the total hip arthroplasty for patients in the experimental group with the assistance of surgical robotic system. the patients in the control group do not use the surgical robotic system. the proportion of acetabular abduction angle and anteversion angle in the lewinnek safe area is the primary outcome measurement. the operation time, womac score, harris score, sf-36 and dislocation rate are the secondary outcome measurements. the incidence of complications, devices and other adverse events were recorded.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of primary hip osteoarthritis(oa), fracture of femoral neck (ffn),or secondary hip osteoarthritis due to developmental dysplasia of the hip (ddh), hip avascular necrosis (avn), rheumatoid arthritis (ra), ankylosing spondylitis (as), and coxa plana exclusion criteria: * severe vascular diseases of the lower extremity neuromuscular diseases infectious diseases severe dysfunctions of major organs severe neurosensory deficiencies caused by spinal diseases unable to receive ct/mri scans
arabic version qol questionnaire chronic wound

Conditions: Chronic Wound

Summary: the aim of this study is to help clinician modification of treatment through assess the validity and reliability of arabic version of 17 items qol questionnaire in patients with chronic wound. it translated to many languages but not present in form of arabic version.

the study will be cross sectional.participants: 100 patients according to sample size calculations suffering from chronic wound with age between 40-60 years. using the minimum acceptable icc of 0.75, expected icc of 0.85, significance level 0.05, statistical power 80% and number of repetitions 2, the required sample size is about 100 subjects.the patients who met the inclusion criteria will be recruited. the purpose, significance, and procedures of the study will be explained to them, and written informed consent will be obtained before enrollment.the researcher will measure the wounds and collect disease-related data during dressing changes. the participants will then be asked to fill out the questionnaires by themselves or with the help of the researcher.each item is scored on a 5-point likert scale from 0 (not at all) to 4 (very much). on obtaining at least 75% response, the researcher calculated a second-order global score as well as scores for every dimension as the mean of the respective responses. higher scores indicated greater impairment of the quality of life.

Eligibility criteria:
inclusion criteria: * patients who suffering from chronic wound at least 1 month prior to study enrollment, * patients aged between 40-60 years .provision of written informed consent. .all participants will be able to read and write in arabic language. .all participants can understand items of the questionnaire. exclusion criteria: * patients who had mental illnesses * patients who were unable to fill in the questionnaire independently or answered the questions orally .patient with communication, vision, hearing disorders. .patient who doesn't fill the questionnaire till the end. * patient who were isolated due to infection

Keywords: validity and reliability. . arabic version qol questionnaire chronic wound
home-based respiratory muscle training for minimizing side effects in patients undergoing treatment for breast cancer

Conditions: Breast Carcinoma

Summary: this clinical trial evaluates whether home-based respiratory muscle training is useful for minimizing side effects in patients undergoing treatment for breast cancer. over-activation of the nervous system during breast cancer treatment can result in heart- and lung-related side effects which have the potential to reduce a patient's quality of life. aerobic exercise can help prevent the development of these side effects. however, engaging in regular aerobic exercise may be difficult for breast cancer patients who are actively undergoing treatment. respiratory muscle training (rmt) involves a series of breathing and other exercises that are performed to improve the function of the respiratory muscles through resistance and endurance training. home-based rmt may represent a more feasible approach for reducing side effects in patients undergoing treatment for breast cancer.

primary objective: i. to assess the feasibility of delivering a 12-week rmt program during adjuvant and neoadjuvant chemotherapy used to treat breast cancer. secondary objectives: i. to determine how cardiac autonomic regulation, cardiorespiratory fitness, exercise performance, and quality-of-life (qol) are affected by rmt during breast cancer treatment. ii. to assess how rmt affects patient reported symptoms linked to sympathetic overactivation such as stress, fatigue, dyspnea, when performed during chemotherapy. exploratory objective: i. to determine if rmt reduces circulating biomarkers of autonomic dysfunction, inflammation, and cardiac injury in breast cancer patients undergoing treatment. outline: patients are randomized to 1 of 2 groups. group i: patients receive lower resistance rmt using a respiratory muscle training device for 12 weeks. group ii: patients undergo higher resistance rmt using a respiratory muscle training device for 12 weeks on study.

Eligibility criteria:
inclusion criteria: * documented breast cancer and scheduled to receive adjuvant or neoadjuvant chemotherapy * age \>= 18 years old * cognitively capable of following direction and performing the intervention * able to speak, read and comprehend english language * understand the investigational nature of this study and sign an independent ethics committee/institutional review board approved written informed consent form prior to receiving any study related procedure exclusion criteria: * have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, heart failure or psychiatric illness/social situations that would limit compliance with study requirements * prior radiation to the left chest wall * patients with medical frailty (clinical discretion) * are pregnant or nursing * unwilling or unable to follow protocol requirements * any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study intervention
noac portuguese real world study

Conditions: Stroke; Systemic Embolism; Major Bleeding

Summary: to determine if there is any difference in the effectiveness and safety outcomes of patients with nvaf newly treated with apixaban, dabigatran, rivaroxaban and vitamin k antagonists


Eligibility criteria:
inclusion criteria: * age ≥18 years on the index date. * at least 1 oac (apixaban, dabigatran, rivaroxaban, vkas) dispensed during the identification period. exclusion criteria: * specialty of the physician responsible for the oac prescription in the index date is one of the following: orthopedics, general surgery, vascular surgery or any other surgical specialty; * duration of oac therapy during follow-up inferior to the cut-off defined during the feasibility assessment (except if the patient was admitted to in-hospital care during follow-up); * the oac dispensed in the index date was one of the following: dabigatran 75 mg or rivaroxaban 10 mg * hospital claims lacking a diagnosis code indicative of af during the study period; * hospital claim indicating a diagnosis or procedure code indicative of pregnancy or childbirth during the study period; * hospital claim indicating a diagnosis or procedure code indicative of valvular heart disease, venous thromboembolism, cardiac surgery, pericarditis, hyperthyroidism and thyrotoxicity during the baseline period; * hospital claim indicating a diagnosis or procedure code indicative of hip and knee replacement surgery during the 6 weeks prior to the index date. patients with past use of oac will be excluded. therefore, patients meeting any of the following criteria will be excluded: * had any oac (apixaban, dabigatran, edoxaban, rivaroxaban, vkas) dispensed during the 12-month baseline period; * had \>1 oac dispensed on the index date.
evaluation of biomarker expression in diabetic and healthy subjects over a one year period

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Healthy

Summary: this study is conducted in the united states of america (usa). the aim of this study is to assess longitudinal variation of immune biomarkers in subjects with type 1 diabetes (t1d), type 2 diabetes (t2d) and healthy, non-diabetic subjects over a one year period.


Eligibility criteria:
inclusion criteria: * t1d * male or female subjects diagnosed within the last 3 years and with good general health based on medical history * age above or equal to 14 years and below or equal to 40 years * body weight above 45 kg * t2d * male or female subjects diagnosed within the last 15 years with good general health based on medical history * hba1c between 6.5% and 10% * body mass index (bmi) below 45 kg/m\^2 * age above or equal to 18 and below 65 years * on insulin treatment * hs * male or female subjects with good general heath based on medical history * age above or equal to 18 years and below or equal to 40 years exclusion criteria: * any chronic disorder (besides t1d or t2d) or severe disease which, in the opinion of the investigator, might jeopardize subject's safety or compliance with the protocol * female of child-bearing potential who is pregnant, breast-feeding, or intends to become pregnant
immersive virtual reality in functional motor disorders

Conditions: Functional Motor Disorders

Summary: the study aims to demonstrate the effectiveness and superiority of a 5-day immersive vr-rehabilitation treatment versus a 5-day conventional rehabilitation treatment in reducing fmds symptoms severity, assessed by the simplified functional movement disorders rating scale (s- fmdrs).

this is a single-blind, randomized controlled trial to evaluate the superiority of immersive vr distractors combined with graded physical exercises over conventional rehabilitation (without any vr distractors) to reduce fmds symptoms and improve gait and balance. patients will be randomized to receive the experimental training (vrg) or the control training (crg) (allocation ratio 1:1). the primary and secondary outcomes will be measured by the same examiner before (t0), at the end of the treatment (t1), and at three-month follow-up after the end of the treatment (t2). the test order will be the same across all evaluation sessions. the examiner will be blinded to group assignments.

Eligibility criteria:
inclusion criteria were: established diagnosis of fmds, age ≥ 18 years, and acceptance of the diagnosis. exclusion criteria were: prominent dissociative seizures, prominent cognitive and/or physical impairment that precluded signing the informed consent form for study participation based on clinical judgment, incomplete assessment, and questionnaire because of language comprehension difficulties.

Keywords: virtual reality
periconceptional iron supplementation in rural bangladesh

Conditions: Anemia

Summary: the investigators hypothesize that periconceptional iron supplementation to married, nulliparous women in rural bangladesh will significantly reduce anemia and improve hemoglobin concentrations before and during pregnancy.

in 2007, the national strategy for anemia prevention and control in bangladesh included adolescents and newly married women as target groups for future iron and folic acid (ifa) supplementation programs. this double-blinded rct examined the effect of daily periconceptional ifa vs. folic acid (fa) on anemia and iron indictors before and during pregnancy among married, nulliparous women in rural bangladesh. biochemical indices were collected at baseline and either at 15 weeks gestation or after 9 months among non-pregnant women (npw).

Eligibility criteria:
inclusion criteria: women were eligible if they were: * married * nulliparous * \< 40 years old * living in the same household as their husband exclusion criteria: women were excluded if they were: * pregnant at enrollment * planning to move out of the region * using iron supplements within the previous 3 months * using an implant form of birth control, or had surgery to prevent pregnancy * women with a hb concentration of \< 70 g/l, defined as severely anemic according to who definition (5), were excluded from the study and appropriately treated

Keywords: periconceptional iron folic acid supplementation
controlled exercises effectiveness in patients with sleep apnea

Conditions: Apnea, Sleep

Summary: the aim is to compare a programme of controlled exercises therapy vs a programme of non controlled exercises therapy in patients with sleep apnea


Eligibility criteria:
inclusion criteria: * sleep apnea exclusion criteria: * neurologic disease
ivc ultrasonography versus plethysmographic variability index for prediction of general anesthesia induction hypotension

Conditions: Hypotension on Induction

Summary: this thesis aims to evaluate the ability of preoperative plethysmographic variability index to predict post-induction hypotension in comparison with ultrasound measurements of inferior vena cava (ivc) diameter.

prospective cohort study. upon arrival to the operating room, routine monitors (ecg, pulse oximetry, and non-invasive blood pressure monitor) will be applied, intravenous line will be secured and routine premedications (ranitidine 50 mg and ondansteron 4mg) will be administrated. then inferior vena cava ultrasonography will be performed. maximum and minimum ivc diameters over a single respiratory cycle will be measured using built-in software. the ci will be calculated as: ci = (divcmax - divcmin)/divcmax , it will be expressed as a percentage. plethysmographic variability index and a perfusion index readings will be taken preinduction in the form of three readings on one-minute interval. induction of anaesthesia will be achieved using propofol (2 mg/kg) and atracurium (0.5 mg/kg). endotracheal tube will be inserted after 3 minutes of mask ventilation. anaesthesia will be maintained by isoflurane (1-1.5%) and atracurium 10 mg increments every 20 minutes. ringer lactate solution will be infused at a rate of 2 ml/kg/hour. any episode of hypotension (defined as mean arterial pressure \< 80% of the baseline reading) will be managed by 5mcg norepinephrine.

Eligibility criteria:
inclusion criteria: * adult patients (\>18years) * asa i-ii-iii * patients scheduled for elective surgeries under general anaesthesia. exclusion criteria: * operations which will last for less than 15 minutes. * patients with cardiac morbidities (impaired contractility with ejection fraction \< 40% and tight valvular lesions, unstable angina). * patients with heart block and arrhythmia (atrial fibrillation and frequent ventricular or supraventricular premature beat). * patient with decompansted respiratory disease (poor functional capacity, generalized wheezes, peripheral o2 saturation \< 90% on room air). * patients with increased intraabdominal pressure (intrabdominal mass compressing ivc). * patients with peripheral vascular disease or long standing dm affecting pvi readings. * pregnancy